Suppr超能文献

阿片类药物诱导的痛觉过敏:对疼痛治疗从业者的临床意义。

Opioid induced hyperalgesia: clinical implications for the pain practitioner.

作者信息

Silverman Sanford M

机构信息

Comprehensive Pain Medicine, Pompano Beach, FL 33064, USA.

出版信息

Pain Physician. 2009 May-Jun;12(3):679-84.

Abstract

Opioids have been and continue to be used for the treatment of chronic pain. Evidence supports the notion that opioids can be safely administered in patients with chronic pain without the development of addiction or chemical dependency. However, over the past several years, concerns have arisen with respect to administration of opioids for the treatment of chronic pain, particularly non-cancer pain. Many of these involve legal issues with respect to diversion and prescription opioid abuse. Amongst these, opioid induced hyperalgesia (OIH) is becoming more prevalent as the population receiving opioids for chronic pain increases. OIH is a recognized complication of opioid therapy. It is a pro-nocioceptive process which is related to, but different from, tolerance. This focused review will elaborate on the neurobiological mechanisms of OIH as well as summarize the pre-clinical and clinical studies supporting the existence of OIH. In particular, the role of the excitatory neurotransmitter, N-methyl-D-aspartate appears to play a central, but not the only, role in OIH. Other mechanisms of OIH include the role of spinal dynorphins and descending facilitation from the rostral ventromedial medulla. The links between pain, tolerance, and OIH will be discussed with respect to their common neurobiology. Practical considerations for diagnosis and treatment for OIH will be discussed. It is crucial for the pain specialist to differentiate amongst clinically worsening pain, tolerance, and OIH since the treatment of these conditions differ. Tolerance is a necessary condition for OIH but the converse is not necessarily true. Office-based detoxification, reduction of opioid dose, opioid rotation, and the use of specific NMDA receptor antagonists are all viable treatment options for OIH. The role of sublingual buprenorphine appears to be an attractive, simple option for the treatment of OIH and is particularly advantageous for a busy interventional pain practice.

摘要

阿片类药物一直以来并将继续用于慢性疼痛的治疗。有证据支持这样一种观点,即阿片类药物可以在慢性疼痛患者中安全使用,而不会产生成瘾或化学依赖。然而,在过去几年中,人们对使用阿片类药物治疗慢性疼痛,尤其是非癌性疼痛产生了担忧。其中许多问题涉及阿片类药物转移和处方阿片类药物滥用的法律问题。在这些问题中,随着接受阿片类药物治疗慢性疼痛的人群增加,阿片类药物诱导的痛觉过敏(OIH)正变得越来越普遍。OIH是阿片类药物治疗公认的并发症。它是一个促伤害感受过程,与耐受性有关,但又有所不同。本综述将详细阐述OIH的神经生物学机制,并总结支持OIH存在的临床前和临床研究。特别是,兴奋性神经递质N-甲基-D-天冬氨酸似乎在OIH中起核心作用,但不是唯一作用。OIH的其他机制包括脊髓强啡肽的作用以及延髓头端腹内侧核的下行易化作用。将从它们共同的神经生物学角度讨论疼痛、耐受性和OIH之间的联系。还将讨论OIH诊断和治疗的实际考虑因素。对于疼痛专家来说,区分临床疼痛恶化、耐受性和OIH至关重要,因为这些情况的治疗方法不同。耐受性是OIH的必要条件,但反之则不一定成立。门诊戒毒、减少阿片类药物剂量、阿片类药物轮换以及使用特定的N-甲基-D-天冬氨酸受体拮抗剂都是治疗OIH的可行选择。舌下含服丁丙诺啡的作用似乎是治疗OIH的一个有吸引力、简单的选择,对于繁忙的介入疼痛治疗实践尤其有利。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验